Cited by 1,557Lipoproteins and Cardiovascular HealthCancer, Lipids, and MetabolismAcute Myocardial Infarction Research

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events

Open access

Ridker, Paul M., Rifai, Nader, Clearfield, Michael, Downs, John R., Weis, Stephen E., Miles, J. Shawn, Gotto, Antonio M.·2001·New England Journal of Medicine

DOI 10.1056/nejm200106283442601

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Elevated levels of C-reactive protein, even in the absence of hyperlipidemia, are associated with an increased risk of coronary events. Statin therapy reduces the level of C-reactive protein independently of its effect on lipid levels. We hypothesized that statins might prevent coronary events in persons with elevated C-reactive protein levels who did not have overt hyperlipidemia. METHODS: The level of C-reactive protein was measured at base line and after one year in 5742 participants in a five-year randomized trial of lovastatin for the primary prevention of acute coronary events. RESULTS: The rates of coronary events increased significantly with increases in the base-line levels of C-reactive protein. Lovastatin therapy reduced the C-reactive protein level by 14.8 percent (P<0.001), an effect not explained by lovastatin-induced changes in the lipid profile. As expected, lovastatin was effective in preventing coronary events in participants whose base-line ratio of total cholesterol to high-density lipoprotein (HDL) cholesterol was higher than the median ratio, regardless of the level of C-reactive protein (number needed to treat for five years to prevent 1 event, 47; P=0.005). However, lovastatin was also effective among those with a ratio of total to HDL cholesterol that was lower than the median and a C-reactive protein level higher than the median (number needed to treat, 43; P=0.02). In contrast, lovastatin was ineffective among participants with a ratio of total to HDL cholesterol and a C-reactive protein level that were both lower than the median (number needed to treat, 983; P=0.80). CONCLUSIONS: Statin therapy may be effective in the primary prevention of coronary events among subjects with relatively low lipid levels but with elevated levels of C-reactive protein.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm200106283442601

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850
Self-citation
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Self-citation
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Self-citation
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Elevated C-reactive protein levels in overweight and obese adults
Visser, M. (1999) · JAMA · doi:10.1001/jama.282.22.2131 · Cited by 2,494
Molecular Bases of the Acute Coronary Syndromes
Libby, P. (1995) · Circulation · doi:10.1161/01.cir.91.11.2844 · Cited by 2,029
C-Reactive Protein, a Sensitive Marker of Inflammation, Predicts Future Risk of Coronary Heart Disease in Initially Healthy Middle-Aged Men
Köenig, W., Sund, M., Fröhlich, M., Fischer, H.-G., Löwel, H., Döring, A., Hutchinson, W. L., & Pepys, M. B. (1999) · Circulation · doi:10.1161/01.cir.99.2.237 · Cited by 1,952

Show all 27 references

Sorted by citations

Items 301–400 of 998

Statins potently reduce the cytokine-mediated IL-6 release in SMC/MNC cocultures
Loppnow, H., Zhang, L., Buerke, M., Lautenschläger, M., Chen, L., Frister, A., Schlitt, A., Luther, T., Song, N., Hofmann, B., et al. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01036.x · Cited by 117
A COmparative study with rosuvastatin in subjects with METabolic Syndrome: results of the COMETS study†
Stalenhoef, A. F. H., Ballantyne, C. M., Sarti, C., Murín, J., Tonstad, S., Rose, H., & Wilpshaar, W. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi482 · Cited by 116
C-REACTIVE PROTEIN LEVELS ARE INFLUENCED BY COMMON IL-1 GENE VARIATIONS
Berger, P. B., McConnell, J. P., Nunn, M. E., Kornman, K. S., Sorrell, J., Stephenson, K. E., & Duff, G. W. (2002) · Cytokine · doi:10.1006/cyto.2001.0974 · Cited by 117
Pitavastatin-Induced Thrombomodulin Expression by Endothelial Cells Acts Via Inhibition of Small G Proteins of the Rho Family
Masamura, K., Oida, K., Kanehara, H., Suzuki, J., Horie, S., Ishii, H., & Miyamori, I. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000060461.64771.f0 · Cited by 117
Standardized capsule of Camellia sinensis lowers cardiovascular risk factors in a randomized, double-blind, placebo-controlled study
Nantz, M. P., Rowe, C. A., Bukowski, J. F., & Percival, S. S. (2008) · Nutrition · doi:10.1016/j.nut.2008.07.018 · Cited by 116
Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology
Tuñón, J., Badimón, L., Bochaton‐Piallat, M., Cariou, B., Daemen, M. J. A. P., Egido, J., Evans, P. C., Hoefer, I. E., Ketelhuth, D. F. J., Lutgens, E., et al. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy293 · Cited by 118
The prevalence of inflammation in carotid atherosclerosis: analysis with fluorodeoxyglucose positron emission tomography
Tahara, N., Kai, H., Nakaura, H., Mizoguchi, M., Ishibashi, M., Kaida, H., Baba, K., Hayabuchi, N., & Imaizumi, T. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm245 · Cited by 116
Inflammatory markers and coronary heart disease
Rifai, N., & Ridker, P. M. (2002) · Current Opinion in Lipidology · doi:10.1097/00041433-200208000-00005 · Cited by 115
Self-citation
Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy
van Wissen, S., Trip, M. D., Smilde, T. J., Graaf, J. D., Stalenhoef, A. F. H., & Kastelein, J. J. P. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(02)00280-0 · Cited by 113
Statins and Inflammation
Satny, M., Hubacek, J. A., & Vrablík, M. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00977-6 · Cited by 121
Comparison of the National Emergency Department Overcrowding Scale and the Emergency Department Work Index for Quantifying Emergency Department Crowding
Weiss, S. J., Ernst, A. A., & Nick, T. G. (2006) · Academic Emergency Medicine · doi:10.1197/j.aem.2005.12.009 · Cited by 113
Vitamin C treatment reduces elevated C-reactive protein
Block, G., Jensen, C. D., Dalvi, T. B., Norkus, E. P., Hudes, M. L., Crawford, P. B., Holland, N., Fung, E. B., Schumacher, L. B., & Harmatz, P. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.09.030 · Cited by 114
C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease: a prospective study
Labarrere, C. A., Lee, J. B., Nelson, D. R., Al‐Hassani, M., Miller, S. J., & Pitts, D. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11473-5 · Cited by 113
Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease – a perspective
KONES, R. J. (2010) · Drug Design Development and Therapy · doi:10.2147/dddt.s10812 · Cited by 112
Selenoproteins, Cholesterol-Lowering Drugs, and the Consequences Revisiting of the Mevalonate Pathway
Moosmann, B., & Behl, C. (2004) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2004.08.003 · Cited by 111
Statins, Inflammation, and Sepsis*
Almog, Y. (2003) · CHEST Journal · doi:10.1378/chest.124.2.740 · Cited by 109
Statins and bone metabolism
Horiuchi, N., & Maeda, T. (2006) · Oral Diseases · doi:10.1111/j.1601-0825.2005.01172.x · Cited by 109
Overview of omega-3 Fatty Acid therapies.
Bradberry, J. C., & Hilleman, D. E. (2013) · PubMed Central · Cited by 109
Statins and inflammation: an update
Quist‐Paulsen, P. (2010) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3283398e53 · Cited by 113
The anti-inflammatory effects of statins on patients with rheumatoid arthritis: A systemic review and meta-analysis of 15 randomized controlled trials
Li, G.-M., Zhao, J., Li, B., Zhang, X., Ma, J., Ma, X., & Liu, J. L. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.10.013 · Cited by 113
C-reactive protein and risk of cardiovascular disease: Evidence and clinical application
Ridker, P. M., Bassuk, S. S., & Toth, P. P. (2003) · Current Atherosclerosis Reports · doi:10.1007/s11883-003-0004-3 · Cited by 108
Self-citation
Association between serum C-reactive protein levels and pulse wave velocity: a population-based cross-sectional study in a general population
Nagano, M., Nakamura, M., Sato, K., Tanaka, F., Segawa, T., & Hiramori, K. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.11.019 · Cited by 108
Diagnostic Implications of C-Reactive Protein
Zimmerman, M. A. (2003) · Archives of Surgery · doi:10.1001/archsurg.138.2.220 · Cited by 108
Anti-atherosclerotic therapies: Milestones, challenges, and emerging innovations
Hetherington, I., & Totary-Jain, H. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.08.024 · Cited by 119
Statin-induced immunomodulatory effects on human T cells in vivo
Fehr, T. H., Kahlert, C. R., Fierz, W., Joller‐Jemelka, H. I., Riesen, W. F., Rickli, H., Wuthrich, R. P., & Ammann, P. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.02.016 · Cited by 107
Critical appraisal of C-reactive protein throughout the spectrum of cardiovascular disease
Osman, R., L’Allier, P. L., Elgharib, N. Z., & Tardif, J. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.3.221 · Cited by 111
Tracking of High-Sensitivity C-Reactive Protein after an Initially Elevated Concentration: The JUPITER Study
Glynn, R. J., MacFadyen, J. G., & Ridker, P. M. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.120642 · Cited by 107
Self-citation
Effects of Combined Administration of Low Dose Atorvastatin and Vitamin E on Inflammatory Markers and Endothelial Function in Patients with Heart Failure
Tousoulis, D., Antoniades, C. A., Vassiliadou, C., Toutouza, M., Pitsavos, C. E., Tentolouris, C. A., Trikas, A. G., & Stefanadis, C. (2005) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2005.03.007 · Cited by 106
Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia
Stein, E. A., Strutt, K., Southworth, H., Diggle, P. J., & Miller, E. (2003) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2003.08.009 · Cited by 106
Statins: the new aspirin?
Veillard, N. R., & Mach, F. (2002) · Cellular and Molecular Life Sciences · doi:10.1007/pl00012505 · Cited by 107
Lipids, atherosclerosis and CVD risk: Is CRP an innocent bystander?
Nordestgaard, B. G., & Zacho, J. (2009) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2009.07.005 · Cited by 101
Repurposing of approved cardiovascular drugs
Ishida, J., Konishi, M., Ebner, N., & Springer, J. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1031-5 · Cited by 103
The Clinical Utility of High-Sensitivity C-Reactive Protein in Cardiovascular Disease and the Potential Implication of JUPITER on Current Practice Guidelines
Mora, S., Musunuru, K., & Blumenthal, R. S. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.109728 · Cited by 100
Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular events
Torres, J. L., & Ridker, P. M. (2003) · Current Opinion in Cardiology · doi:10.1097/00001573-200311000-00008 · Cited by 101
Self-citation
Patient survival after renal transplantation III: The effects of statins
Cosio, F. G., Pesavento, T. E., Pelletier, R. P., Henry, M. L., Ferguson, R. M., Kim, S. W., & Lemeshow, S. A. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.34927 · Cited by 101
Rethinking Primary Prevention of Atherosclerosis-Related Diseases
Claudio Napoli, A., Lerman, L. O., de Nigris, F., Gössl, M., Balestrieri, M. L., & Lerman, A. (2006) · Circulation · doi:10.1161/circulationaha.105.570358 · Cited by 102
The metabolic syndrome
Sarti, C., & Gallagher, J. C. (2006) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2005.06.014 · Cited by 98
Isoprenoid metabolism and the pleiotropic effects of statins
Laufs, U., & Liao, J. K. (2003) · Current Atherosclerosis Reports · doi:10.1007/s11883-003-0008-z · Cited by 100
Atherogenesis: the role of inflammation and infection
Mahmoudi, M., Curzen, N. P., & Gallagher, P. J. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02503.x · Cited by 99
The implication of proinflammatory cytokines in type 2 diabetes
Christopher, B. G. (2008) · Frontiers in bioscience · doi:10.2741/3074 · Cited by 99
CRP after 2004
Agrawal, A. C. (2004) · Molecular Immunology · doi:10.1016/j.molimm.2004.09.028 · Cited by 98
Dietary Cod Protein Reduces Plasma C-Reactive Protein in Insulin-Resistant Men and Women3
Ouellet, V., Weisnagel, S. J., Marois, J., Bergeron, J., Julien, P., Gougeon, R., Tchernof, A., Holub, B. J., & Jacques, H. (2008) · Journal of Nutrition · doi:10.3945/jn.108.092346 · Cited by 98
Statin use and survival in patients with chronic heart failure — results from two observational studies with 5200 patients
Anker, S. D., Clark, A. L., Winkler, R., Zugck, C., Cicoira, M., Ponikowski, P. P., Davos, C. H., Banasiak, W., Zardini, P., Haass, M., et al. (2006) · International Journal of Cardiology · doi:10.1016/j.ijcard.2006.03.057 · Cited by 97
Comparative Effectiveness of 12 Treatment Strategies for Preventing Contrast-Induced Acute Kidney Injury: A Systematic Review and Bayesian Network Meta-analysis
Su, X., Xie, X., Liu, L., Lv, J., Song, F., Perkovic, V., & Zhang, H. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.07.033 · Cited by 95
Clinical Implications of the Cytokine Hypothesis of Depression: The Association between Use of Statins and Aspirin and the Risk of Major Depression
Pasco, J. A., Jacka, F. N., Williams, L. J., Henry, M. J., Nicholson, G. C., Kotowicz, M. A., & Berk, M. (2010) · Psychotherapy and Psychosomatics · doi:10.1159/000319530 · Cited by 95
Efficacy of Short-Term High-Dose Statin in Preventing Contrast-Induced Nephropathy: A Meta-Analysis of Seven Randomized Controlled Trials
Li, Y., Liu, Y., Fu, L., Mei, C., & Dai, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034450 · Cited by 95
Colocalisation of intraplaque C reactive protein, complement, oxidised low density lipoprotein, and macrophages in stable and unstable angina and acute myocardial infarction
Meuwissen, M., van der Wal, A. C., Niessen, H. W. M., Koch, K. T., de Winter, R. J., van der Loos, C. M., Rittersma, S. Z. H., Chamuleau, S. A. J., Tijssen, J. G. P., Becker, A. E., et al. (2006) · Journal of Clinical Pathology · doi:10.1136/jcp.2005.027235 · Cited by 94
Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice
Fujii, M., Inoguchi, T., Maeda, Y., Sasaki, S., Sawada, F., Saito, R., Kobayashi, K., Sumimoto, H., & Takayanagi, R. (2007) · Kidney International · doi:10.1038/sj.ki.5002366 · Cited by 92
Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome
Link, A., Ayadhi, T., Böhm, M., & Nickenig, G. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl277 · Cited by 93
High Sensitivity C-reactive Protein (hsCRP) and its Implications in Cardiovascular Outcomes
Denegri, A., & Boriani, G. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200717090334 · Cited by 98
Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: Results of the CAP (Comparative Atorvastatin Pleiotropic effects) study
Bonnet, J., McPherson, R., Tedgui, A., Simoneau, D., Nozza, A., Martineau, P., & Davignon, J. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.12.023 · Cited by 92
Clinical implications of inflammation for cardiovascular primary prevention
Libby, P., & Crea, F. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq022 · Cited by 91
Statins, inflammation and kidney disease
Krane, V., & Wanner, C. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.62 · Cited by 89
Traditional Chinese medication Tongxinluo dose-dependently enhances stability of vulnerable plaques: a comparison with a high-dose simvastatin therapy
Zhang, L., Liu, Y., Lu, X. T., Wu, Y. L., Zhang, C., Ji, X. P., Wang, R., Liu, C. X., Feng, J. B., Jiang, H., et al. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00208.2009 · Cited by 90
The relation of C-reactive protein levels to total and cardiovascular mortality in older U.S. women
Tice, J. A., Browner, W. S., Tracy, R. P., & Cummings, S. R. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01497-3 · Cited by 91
Stat3 Mediates Interelukin-6 Inhibition of Human Endothelial Nitric-oxide Synthase Expression
Saura, M., Zaragoza, C., Bao, C., Herránz, B., Rodrı́guez-Puyol, M., & Lowenstein, C. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606279200 · Cited by 90
Association between Serum C-reactive Protein Levels and Microalbuminuria: A Population-Based Cross-Sectional Study in Northern Iwate, Japan
Nakamura, M., Onoda, T., Itai, K., Ohsawa, M., Satou, K., Sakai, T., Segawa, T., Sasaki, J., Tonari, Y., Hiramori, K., et al. (2004) · Internal Medicine · doi:10.2169/internalmedicine.43.919 · Cited by 90
Mevastatin inhibits ovarian theca–interstitial cell proliferation and steroidogenesis
Izquierdo, D. M., Foyouzi, N., Kwintkiewicz, J., & Dulęba, A. J. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.03.037 · Cited by 90
High-sensitivity C-reactive protein as a biomarker of risk in coronary artery disease
Silva, D., & de Lacerda, A. P. (2012) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2012.09.006 · Cited by 90
Metabolic Effects of Infection on Protein and Energy Status
Powanda, M. C., & Beisel, W. R. (2003) · Journal of Nutrition · doi:10.1093/jn/133.1.322s · Cited by 89
Fasting Serum C‐Peptide Levels Predict Cardiovascular and Overall Death in Nondiabetic Adults
Patel, N., Taveira, T. H., Choudhary, G., Whitlatch, H. B., & Wu, W. (2012) · Journal of the American Heart Association · doi:10.1161/jaha.112.003152 · Cited by 89
Inflammation and Cardiovascular Disease: The Future
Arnold, N., Lechner, K., Waldeyer, C., Shapiro, M. D., & Köenig, W. (2021) · European Cardiology Review · doi:10.15420/ecr.2020.50 · Cited by 93
C-Reactive Protein Is an Independent Predictor of Mortality in Women With HIV-1 Infection
Feldman, J. G., Goldwasser, P., Holman, S., DeHovitz, J. A., & MINKOFF, H. L. (2003) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200302010-00014 · Cited by 87
Prediction of cardiovascular risk using soluble cell adhesion molecules
Mulvihill, N. T. (2002) · European Heart Journal · doi:10.1053/euhj.2002.3188 · Cited by 86
Moving Beyond JUPITER: Will Inhibiting Inflammation Reduce Vascular Event Rates?
Ridker, P. M. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0295-3 · Cited by 86
Self-citation
Clinical approach to the inflammatory etiology of cardiovascular diseases
Ruscica, M., Corsini, A., Ferri, N., Banach, M., & Sirtori, C. R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104916 · Cited by 87
Cardiovascular Biomarkers in CKD: Pathophysiology and Implications for Clinical Management of Cardiac Disease
Roberts, M. A., Hare, D. L., Ratnaike, S., & Ierino, F. L. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.06.005 · Cited by 86
C-Reactive Protein As a Marker of Melanoma Progression
Fang, S., Wang, Y., Sui, D., Liu, H., Ross, M. I., Gershenwald, J. E., Cormier, J. N., Royal, R. E., Lucci, A., Schacherer, C. W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0209 · Cited by 86
Effect of a plant stanol ester-containing spread, placebo spread, or Mediterranean diet on estimated cardiovascular risk and lipid, inflammatory and haemostatic factors
Athyros, V. G., Kakafika, A. I., Papageorgiou, A. A., Τζιόμαλος, Κ., Peletidou, A., Vosikis, C., Karagiannis, A. I., & Mikhailidis, D. P. (2009) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2009.08.014 · Cited by 85
Statins and Renal Function
Elisaf, M., & Mikhailidis, D. P. (2002) · Angiology · doi:10.1177/000331970205300501 · Cited by 85
Utility of inflammatory markers in the management of coronary artery disease
Rosenson, R. S., & Köenig, W. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00504-6 · Cited by 85
Inflammatory Biomarkers in Stable Atherosclerosis
Kinlay, S., & Egido, J. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.09.014 · Cited by 84
Statins and sepsis.
Gao, F., Linhartova, L., Johnston, A. M., & Thickett, D. R. (2008) · British Journal of Anaesthesia · doi:10.1093/bja/aem406 · Cited by 83
Targeting inflammation to reduce recurrent stroke
Zietz, A., Gorey, S., Kelly, P. J., Mira, K., & McCabe, J. J. (2023) · International Journal of Stroke · doi:10.1177/17474930231207777 · Cited by 90
A practical approach to risk assessment to prevent coronary artery disease and its complications
Linton, M. F., & Fazio, S. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00505-8 · Cited by 83
HOCHUEKKITO IMPROVES SYSTEMIC INFLAMMATION AND NUTRITIONAL STATUS IN ELDERLY PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Tatsumi, K., Shinozuka, N., Nakayama, K., SEKIYA, N., Kuriyama, T., & Fukuchi, Y. (2008) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2009.02034.x · Cited by 83
There Is No Evidence for an Increase in Acute Coronary Syndromes After Short-Term Abrupt Discontinuation of Statins in Stable Cardiac Patients
McGowan, M. P. (2004) · Circulation · doi:10.1161/01.cir.0000145118.55201.15 · Cited by 83
Role of C-Reactive Protein in Cardiovascular Disease
Backes, J. M., Howard, P. A., & Moriarty, P. M. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1d203 · Cited by 81
A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms
Hironori Nakagami, A., Jensen, K. S., & Liao, J. K. (2003) · Annals of Medicine · doi:10.1080/07853890310001294 · Cited by 83
Influence of HMG–CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion
Bickel, C., Rupprecht, H. J., Blankenberg, S., Espinola–Klein, C., Rippin, G., Hafner, G., Lotz, J., Prellwitz, W., & Meyer, J. (2002) · International Journal of Cardiology · doi:10.1016/s0167-5273(01)00576-9 · Cited by 83
Medical Lipid-Regulating Therapy
Evans, M., Roberts, A. W., Davies, S., & Rees, A. (2004) · Drugs · doi:10.2165/00003495-200464110-00003 · Cited by 81
Plasma C-Reactive Protein Concentrations in Active and Passive Smokers: Influence of Antioxidant Supplementation
Block, G., Jensen, C. D., Dietrich, M., Norkus, E. P., Hudes, M. L., & Packer, L. (2004) · Journal of the American College of Nutrition · doi:10.1080/07315724.2004.10719354 · Cited by 82
Rosuvastatin 1.2 mg In Situ Gel Combined With 1:1 Mixture of Autologous Platelet‐Rich Fibrin and Porous Hydroxyapatite Bone Graft in Surgical Treatment of Mandibular Class II Furcation Defects: A Randomized Clinical Control Trial
Pradeep, A. R., Karvekar, S., Nagpal, K., Patnaik, K., Raju, A. P., & Singh, P. (2015) · Journal of Periodontology · doi:10.1902/jop.2015.150131 · Cited by 82
Statins and stroke: evidence for cholesterol-independent effects
Napoli, P. D. (2002) · European Heart Journal · doi:10.1053/euhj.2002.3236 · Cited by 83
C-reactive protein and coronary artery disease: influence of obesity, caloric restriction and weight loss
Heilbronn, L. K., & Clifton, P. M. (2002) · The Journal of Nutritional Biochemistry · doi:10.1016/s0955-2863(02)00187-0 · Cited by 80
Hormone Replacement Therapy and Inflammation
Miller, A. P., Chen, Y.-F., Xing, D., Feng, W., & Oparil, S. (2003) · Hypertension · doi:10.1161/01.hyp.0000085560.02979.0c · Cited by 81
Inflammatory markers are associated with left ventricular hypertrophy and diastolic dysfunction in a population-based sample of elderly men and women
Masiha, S., Sundström, J., & Lind, L. (2012) · Journal of Human Hypertension · doi:10.1038/jhh.2011.113 · Cited by 80
Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis
Krane, V., for the German Diabetes and Dialysis Study Investigators, Winkler, K., Drechsler, C., Lilienthal, J., März, W., & Wanner, C. (2008) · Kidney International · doi:10.1038/ki.2008.484 · Cited by 79
Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein
Köenig, W. (2004) · International Journal of Cardiology · doi:10.1016/j.ijcard.2004.05.019 · Cited by 81
Reduction of oxidative stress and modulation of autoantibodies against modified low‐density lipoprotein after rosuvastatin therapy
Resch, U., Tatzber, F., Budinsky, A. C., & Sinzinger, H. F. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02568.x · Cited by 80
High-sensitivity C-reactive protein as a risk assessment tool for cardiovascular disease
Yeh, E. T. H. (2005) · Clinical Cardiology · doi:10.1002/clc.4960280905 · Cited by 81
POOR NUTRITIONAL STATUS AND INFLAMMATION: C‐Reactive Protein and End‐Stage Renal Disease
Lacson, E., & Levin, N. W. (2004) · Seminars in Dialysis · doi:10.1111/j.0894-0959.2004.17604.x · Cited by 80
Long-Term Effects of Inflammation-Sensitive Plasma Proteins and Systolic Blood Pressure on Incidence of Stroke
Engström, G., Lind, P., Hedblad, B., Stavenow, L., Janzon, L., & Lindgärde, F. (2002) · Stroke · doi:10.1161/01.str.0000034787.02925.1f · Cited by 80
A serum amyloid A and LDL complex as a new prognostic marker in stable coronary artery disease
Ogasawara, K., Mashiba, S., Wada, Y., Sahara, M., UCHIDA, K., Aizawa, T., & Kodama, T. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.01.030 · Cited by 79
Blocking Interleukin-1 as a Novel Therapeutic Strategy for Secondary Prevention of Cardiovascular Events
Abbate, A., Tassell, B. W. V., & Biondi‐Zoccai, G. (2012) · BioDrugs · doi:10.1007/bf03261881 · Cited by 78
Inflammation and Atherosclerosis in End-Stage Renal Disease
Zoccali, C., Mallamaci, F., & Tripepi, G. L. (2003) · Blood Purification · doi:10.1159/000067852 · Cited by 79
High‐Sensitivity C‐Reactive Protein Discordance With Atherogenic Lipid Measures and Incidence of Atherosclerotic Cardiovascular Disease in Primary Prevention: The ARIC Study
Quispe, R., Michos, E. D., Martin, S. S., Puri, R., Toth, P. P., Suwaidi, J. M. S. A., Banach, M., Virani, S. S., Blumenthal, R. S., Jones, S. R., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.013600 · Cited by 78
Endothelial Dysfunction, Inflammation and Diabetes
Dandona, P., Aljada, A., Chaudhuri, A., & Mohanty, P. (2004) · Reviews in Endocrine and Metabolic Disorders · doi:10.1023/b:remd.0000032407.88070.0a · Cited by 79
Statin Attenuates Increase in C-Reactive Protein During Estrogen Replacement Therapy in Postmenopausal Women
Koh, K. K., Schenke, W. H., Waclawiw, M. A., Csákó, G., & Cannon, R. O. (2002) · Circulation · doi:10.1161/01.cir.0000013837.81710.da · Cited by 78
Immune-regulation of the apolipoprotein A-I/C-III/A-IV gene cluster in experimental inflammation
Navarro, M. Á., Carpintero, R., Acı́n, S., Arbonés-Mainar, J. M., Calleja, L., Carnicer, R., Surra, J. C., Guzmán-García, M. A., González‐Ramón, N., Iturralde, M., et al. (2005) · Cytokine · doi:10.1016/j.cyto.2005.03.002 · Cited by 79

Authors: Ridker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto, A. M.
Affiliations: Brigham and Women's Hospital (US)
University of North Texas Health Science Center (US)
Wilford Hall Ambulatory Surgical Center (US)
ORCID: Ridker, Paul M.
Rifai, Nader
Weis, Stephen E.
Gotto, Antonio M.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2001-06-28
Volume: 344
Issue: 26
Pages: 1959-1965
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm200106283442601
OpenAlex: W2316243284
Cited by: 1,557
References: 27
Citations by year: 2026: 12 · 2025: 19 · 2024: 16 · 2023: 29 · 2022: 34 · 2021: 30 · 2020: 35 · 2019: 38 · 2018: 29 · 2017: 25 · 2016: 39 · 2015: 41 · 2014: 39 · 2013: 43 · 2012: 52
FWCI: 158.00
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: Doris Duke Charitable Foundation
American Heart Association
Fondation Leducq
National Heart, Lung, and Blood Institute (R01HL058755, HL-58755)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords: C-reactive protein, statin therapy, lovastatin, primary prevention, acute coronary events, cardiovascular risk stratification, TC/HDL-C ratio, hyperlipidemia, inflammation, number needed to treat
MeSH terms: Acute Disease, Anticholesteremic Agents, C-Reactive Protein, Cholesterol, Coronary Disease, Double-Blind Method, Follow-Up Studies, Humans, Cholesterol, HDL, Lovastatin, Primary Prevention, Risk, Risk Factors, Proportional Hazards Models, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks